| P50 | author | Greet Van den Berghe | Q41203524 |
| | Michael P Casaer | Q57647247 |
| | Holger Jon Møller | Q67984452 |
| | Greet De Vlieger | Q92374172 |
| | Philippe Meersseman | Q114448782 |
| P2093 | author name string | Greet Hermans | |
| | Ilse Vanhorebeek | |
| | Pieter J Wouters | |
| | Philippe Meersseman | |
| | Catherine Ingels | |
| | Inge Derese | |
| | Yves Debaveye | |
| P2860 | cites work | Fungal recognition enhances mannose receptor shedding through dectin-1 engagement | Q24609870 |
| | Interactions of fungal pathogens with phagocytes | Q28273024 |
| | The mannose receptor | Q28274841 |
| | APACHE II: a severity of disease classification system | Q29547729 |
| | Molecular and nonmolecular diagnostic methods for invasive fungal infections | Q34057660 |
| | Monocyte expression and soluble levels of the haemoglobin receptor (CD163/sCD163) and the mannose receptor (MR/sMR) in septic and critically ill non-septic ICU patients | Q35122854 |
| | The Effect of Inadequate Initial Empiric Antimicrobial Treatment on Mortality in Critically Ill Patients with Bloodstream Infections: A Multi-Centre Retrospective Cohort Study | Q36010587 |
| | The late phase of sepsis is characterized by an increased microbiological burden and death rate | Q36070469 |
| | Early versus late parenteral nutrition in ICU patients: cost analysis of the EPaNIC trial | Q36633647 |
| | Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/ | Q37164067 |
| | (1, 3)-β-D-glucan assay for diagnosing invasive fungal infections in critically ill patients with hematological malignancies | Q37225323 |
| | Empirical Micafungin Treatment and Survival Without Invasive Fungal Infection in Adults With ICU-Acquired Sepsis, Candida Colonization, and Multiple Organ Failure: The EMPIRICUS Randomized Clinical Trial | Q40502784 |
| | The novel biomarker of alternative macrophage activation, soluble mannose receptor (sMR/sCD206): Implications in multiple myeloma. | Q40743206 |
| | Pneumocystis carinii enhances soluble mannose receptor production by macrophages | Q40851237 |
| | Failure of empirical systemic antifungal therapy in mechanically ventilated critically ill patients | Q41204913 |
| | Increased concentrations of the soluble mannose receptor in serum from patients with pneumococcal bacteraemia, and prediction of survival | Q41480967 |
| | Preoperative serum macrophage activated biomarkers soluble mannose receptor (sMR) and soluble haemoglobin scavenger receptor (sCD163), as novel markers for the diagnosis and prognosis of gastric cancer | Q41612982 |
| | Macrophage-related serum biomarkers soluble CD163 (sCD163) and soluble mannose receptor (sMR) to differentiate mild liver fibrosis from cirrhosis in patients with chronic hepatitis C: a pilot study | Q42232930 |
| | International study of the prevalence and outcomes of infection in intensive care units | Q44988294 |
| | ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 |
| | The macrophage activation marker sMR as a diagnostic and prognostic marker in patients with acute infectious disease with or without sepsis | Q48135948 |
| | Early versus Late Parenteral Nutrition in Critically Ill Adults | Q57245243 |
| | Impact of supplemental parenteral nutrition early during critical illness on invasive fungal infections: a secondary analysis of the EPaNIC randomized controlled trial | Q61820609 |
| | A soluble form of the macrophage-related mannose receptor (MR/CD206) is present in human serum and elevated in critical illness | Q86506307 |
| P433 | issue | 1 | |
| P921 | main subject | invasive fungal infections | Q55022218 |
| P304 | page(s) | 270 | |
| P577 | publication date | 2019-08-02 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | The soluble mannose receptor (sMR/sCD206) in critically ill patients with invasive fungal infections, bacterial infections or non-infectious inflammation: a secondary analysis of the EPaNIC RCT | |
| P478 | volume | 23 | |